William Blair analyst Matt Phipps initiated coverage of Climb Bio (CLYM) with an Outperform rating and no price target The firm cites the potential of the company’s CD19 antibody, budoprutug, which is being developed across a range of autoimmune indications, for the rating. The simplicity of a monoclonal antibody will be attractive for community physicians who treat most autoimmune patients, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLYM: